IL6R and metastatic neoplasm: The majority of patients dying from their malignant disease (metastatic disease at the time of diagnosis, later death from relapse) were included in a cluster characterized by especially higher levels of IL6, IL33Rα, and TNFα compared to the other main cluster, whereas IL1RA and CRP only showed differences with borderline significance.